Profund Advisors LLC raised its position in TESARO, Inc. (NASDAQ:TSRO) by 3.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,562 shares of the biopharmaceutical company’s stock after buying an additional 93 shares during the period. Profund Advisors LLC’s holdings in TESARO were worth $394,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Analysts LLC acquired a new position in TESARO during the fourth quarter worth approximately $134,000. Massmutual Trust Co. FSB ADV purchased a new stake in TESARO during the fourth quarter worth about $134,000. Pacer Advisors Inc. purchased a new stake in TESARO during the third quarter worth about $216,000. Endurant Capital Management LP purchased a new stake in TESARO during the third quarter worth about $341,000. Finally, Bank of Montreal Can increased its stake in TESARO by 649.5% in the first quarter. Bank of Montreal Can now owns 2,286 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 1,981 shares during the last quarter.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Shares of TESARO, Inc. (NASDAQ:TSRO) traded up 0.06% on Friday, reaching $144.31. The company had a trading volume of 965,028 shares. The company has a 50 day moving average of $145.90 and a 200-day moving average of $151.16. The company’s market capitalization is $7.77 billion. TESARO, Inc. has a 52 week low of $36.71 and a 52 week high of $192.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. During the same period in the prior year, the company earned ($2.22) EPS. The company’s revenue for the quarter was up 909.8% compared to the same quarter last year. Analysts predict that TESARO, Inc. will post ($8.74) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “TESARO, Inc. (TSRO) Position Increased by Profund Advisors LLC” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/16/tesaro-inc-tsro-position-increased-by-profund-advisors-llc-updated-updated.html.

TSRO has been the subject of a number of recent analyst reports. Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a “buy” rating in a report on Thursday, March 2nd. Argus started coverage on TESARO in a report on Friday, March 24th. They set a “buy” rating and a $210.00 price objective for the company. Citigroup Inc. reiterated a “buy” rating and issued a $216.00 target price (down from $232.00) on shares of TESARO in a report on Saturday, April 22nd. Oppenheimer Holdings, Inc. set a $199.00 target price on TESARO and gave the stock a “buy” rating in a report on Sunday, June 4th. Finally, Cann reiterated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Monday, June 5th. Nine analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $174.32.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $153.02, for a total transaction of $126,853.58. Following the completion of the sale, the senior vice president now directly owns 6,522 shares in the company, valued at approximately $997,996.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The disclosure for this sale can be found here. Corporate insiders own 40.50% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.